[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Burz C, Berindan-Neagoe IB, Balacescu O, Tanaselia C, Ursu M, Gog A, Vlase L, Chintoanu M, Balacescu L, Leucuta SE, Irimie A, Cristea V: Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. J Gastrointestin Liver Dis; 2009 Mar;18(1):39-43
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
  • AIM: to evaluate the therapeutic efficacy of oxaliplatin and to analyze the pharmacokinetics of both ultrafiltrable (free) and protein-bound platinum in patients with metastatic colon cancer.
  • METHOD: 60 patients with stage IV colon carcinoma received 4-6 (mean 4.5) cycles of oxaliplatin based combination chemotherapy.
  • The pharmacokinetics of oxaliplatin was evaluated in 8 patients who were given 85 mg/sqm or 130 mg/sqm using an infusion time of 2-4 h.
  • The median time of progression was 9.3 months.
  • CONCLUSION: Oxaliplatin is active and well tolerated in patients with advanced colon cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Colonic Neoplasms / drug therapy. Organoplatinum Compounds / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Area Under Curve. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / blood. Fluorouracil / pharmacokinetics. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leucovorin / blood. Leucovorin / pharmacokinetics. Male. Mass Spectrometry. Metabolic Clearance Rate. Middle Aged. Neoplasm Staging. Protein Binding. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337632.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


2. Osuagwu CC, Okafor OC, Ezeome ER, Uche CE, Ememonu C, Kesieme E: Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male. Rare Tumors; 2010;2(4):e66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial adenomatous polyposis with synchronous invasive colonic carcinomas and metastatic jejunal adenocarcinoma in a Nigerian male.
  • An intriguing feature of this case is an ulcerated jejunal carcinoma which was metastatic rather than synchronous carcinoma.
  • This patient presented with partial large bowel obstruction and the pathological analysis revealed 4 invasive adenocarcinomas, 3 in the colon and 1 in the jejunum (Dukes stage D).
  • Palliative pancolectomy and jejunal tumour resection with chemotherapy was offered to him.
  • The challenges of managing a hereditary cancer syndrome in a resource poor country are highlighted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Nov 14;14(42):6531-5 [19030207.001]
  • [Cites] East Afr Med J. 1995 Apr;72(4):267-8 [7621765.001]
  • [Cites] West Afr J Med. 2001 Oct-Dec;20(4):251-5 [11885882.001]
  • [Cites] Cent Afr J Med. 1992 Jan;38(1):44-8 [1321689.001]
  • [Cites] Niger J Med. 2005 Apr-Jun;14(2):161-6 [16083239.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cent Afr J Med. 1994 Jan;40(1):8-13 [8082150.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] JOP. 2008;9(1):9-18 [18182737.001]
  • [Cites] Neth J Med. 1989 Jun;34(5-6):317-21 [2549435.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1982-7 [8247073.001]
  • [Cites] Dis Colon Rectum. 1996 May;39(5):536-40 [8620804.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • (PMID = 21234258.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019601
  • [Keywords] NOTNLM ; adenocarcinoma. / colon / familial adenomatous polyposis / jejunum
  •  go-up   go-down


3. Molnar B, Ladanyi A, Tanko L, Sréter L, Tulassay Z: Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res; 2001 Dec;7(12):4080-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients.
  • PURPOSE: Recently several reverse transcription-PCR techniques have been proven to be useful for the detection of circulating micrometastases.
  • In this study, evaluation and modification of a commercial, cytokeratin-based, immunomagnetic cell separation method was performed for the detection of intact cell clusters in colorectal carcinoma patients.
  • EXPERIMENTAL DESIGN: Thirty-two colon cancer patients (6 were in Dukes stage B, 13 in stage C, and 13 in stage D) and 20 healthy donor samples were evaluated.
  • Immunomagnetic cell separation was performed from the buffy coat of peripheral blood samples (20 ml) using the Carcinoma Cell Enrichment Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), avoiding any filtering steps.
  • Follow-up data indicate that chemotherapy cannot destroy all of the circulating tumor cell clusters.
  • CONCLUSIONS: Using the methods presented, we could detect circulating colon cancer cells and cell clusters in colon carcinoma patients.
  • Present data prove that such structures are present in human colorectal cancer, too.
  • [MeSH-major] Colonic Neoplasms / blood. Colorectal Neoplasms / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2002 Jun;8(6):2015; author reply 2016-7 [12060648.001]
  • (PMID = 11751505.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


Advertisement
4. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, Iacopetta B: p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology; 2000;58(1):52-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.
  • Two common genetic alterations in colon carcinoma, p53 mutation and microsatellite instability (MSI), were investigated to determine their prognostic importance for cancer-specific survival and response to adjuvant chemotherapy in patients with Dukes' C colon cancer.
  • The cellular response mechanisms to DNA-damaging agents in tumours with mutant p53 or MSI may as a consequence differ, and this might translate into different outcomes following adjuvant chemotherapy.
  • A consecutive series of 388 Dukes' C colon carcinomas with 5-year median follow-up was analysed for p53 mutation and for MSI (in proximal/transverse carcinomas only) using polymerase chain reaction single-strand conformation polymorphism.
  • One hundred and thirty-three patients (34%) received adjuvant chemotherapy (5-fluorouracil/levamisole) with curative intent.
  • The presence of MSI in the proximal/transverse colon carcinoma group was associated with significantly better 5-year survival: 58 versus 32% (p = 0.015, log rank test).
  • This was largely due to better survival observed in the MSI subgroup that received adjuvant chemotherapy (p = 0.017, log rank test).
  • Further work in prospective, randomised clinical trials investigating the effects of adjuvant therapy should consider incorporating MSI status in order to determine whether this is an independent predictive factor for survival and/or response to adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / genetics. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Genes, p53 / genetics. Microsatellite Repeats. Mutation
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Levamisole / administration & dosage. Male. Neoplasm Staging. Polymerase Chain Reaction / methods. Polymorphism, Single-Stranded Conformational. Predictive Value of Tests. Prognosis. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10644941.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Belhadj N, Gargouri D, Kharrat J, Ben Hriz F, Kochlef A, Kilani A, Romani M, Ghorbel A, Cherif R, Khlifi S, Ben Maamer A, Letaief A: [A gastroenterology unit experience with adjuvant chemotherapy for non-metastatic colon cancer: results from 24 cases]. Tunis Med; 2003 Jun;81(6):395-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A gastroenterology unit experience with adjuvant chemotherapy for non-metastatic colon cancer: results from 24 cases].
  • [Transliterated title] Chimiotherapie adjuvante des cancers coliques non metastatiques. Expérience d'un service de gastro-entérologie. A propos de 24 cas.
  • A prospective study was carried from January 1996 to December 2000 including patients that received adjuvant chemotherapy type FUFOL for colon carcinoma after curative surgery.
  • Chemotherapy was recommended for all stage Dukes B2 end C.
  • Adjuvant chemotherapy was administered to 24 patients (13 men and 11 women, mean age 56.7 +/- 11.5 years) with surgically resected stage B 2 in 7 cases (29%), C in 17 cases (71%).
  • Treatment was completed in 15 patients (62%).
  • With a median follow-up of 31.6 months, 11 patients had no recurrence, one patient had locoregional recurrence and 2 patients developed liver metastasis.
  • Adjuvant FUFOL chemotherapy is actually the recommended adjuvant post-surgical treatment for colon cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma / drug therapy. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Leucovorin / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Hospital Units. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534945.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G, ACOI/GIVIO/GISCAD Investigators: Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst; 2004 May 19;96(10):750-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
  • BACKGROUND: 5-fluorouracil-based adjuvant chemotherapy after surgical resection of colon cancer is standard treatment.
  • In a randomized clinical trial of patients with colon cancer, we compared the benefits of chemotherapy delivered by these routes individually or in combination.
  • METHODS: From April 2, 1992, through April 30, 1998, 1084 eligible patients with Dukes' stage B or C colon carcinoma were randomly assigned: 369 patients to the IP regimen (continuous portal vein infusion of 5-fluorouracil at 500 mg/m2 of body surface daily and heparin at 5000 IU daily for 7 consecutive days, beginning on the day of surgery), 358 patients to the SY regimen (six 28-day courses of systemic leucovorin at 100 mg/m2 daily on days 1 through 5 followed by systemic bolus 5-fluorouracil at 370 mg/m2 daily on days 1 through 5, with treatment initiated 15-35 days after surgery), and 357 patients to the IP+SY regimen (the IP regimen followed by the SY regimen, with the same scheduling).
  • RESULTS: At a median follow-up time of 99 months, 389 events (recurrences, second malignancies, or deaths) had occurred, and 361 patients died.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Portal Vein
  • [MeSH-minor] Administration, Oral. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Italy. Leucovorin / administration & dosage. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Research Design. Risk Factors. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2004 May 19;96(10):727-9 [15150295.001]
  • (PMID = 15150303.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Check JH, Dix E, Sansoucie L, Check D: Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report. Anticancer Res; 2009 May;29(5):1611-3
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report.
  • BACKGROUND: Mifepristone, a progesterone receptor antagonist has been found to improve the length and quality of life in various spontaneous murine cancer models including tumors without progesterone receptors theoretically by inhibiting an immunomodulatory protein that suppresses natural killer cell function in the tumor microenvironment.
  • MATERIALS AND METHODS: Mifepristone 200 mg per day by mouth was given to two patients with stage 4 colon cancer with extensive metastases.
  • Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow.
  • The drug was extremely well tolerated.
  • CONCLUSION: The use of progesterone receptor antagonists may present a novel immunotherapy to help fight cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy. Mifepristone / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443374.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 320T6RNW1F / Mifepristone
  •  go-up   go-down


8. Mross K, Semsek D: [Chemotherapy of colonic carcinoma in the year 2001]. Praxis (Bern 1994); 2001 Mar 22;90(12):497-510
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of colonic carcinoma in the year 2001].
  • [Transliterated title] Die Chemotherapie des Kolonkarzinoms im Jahr 2001.
  • The systemic anticancer drug therapy is indicated in the adjuvant as well as in the palliative setting.
  • There is an indication for an adjuvant therapy in case of Dukes B (stadium II) as well as in Dukes C (stadium III) colon cancer.
  • An indication in the palliative setting remains for the Dukes D (stadium IV) colon cancer patients.
  • Locoregional chemotherapeutical approaches represent no standard procedure and cannot be recommended outside clinical trials because the real value of this therapy is unknown due to a lack of large randomized trials.
  • The mainstay of treatment of colon cancer is 5-Fluoruracil (5-FU), which should be combined with folinic acid in case of bolus (2-4 min. injection) therapy.
  • In the adjuvant situation the Mayo scheme administered over a period of half a year remains the standard of choice because this procedure is validated by large randomized trials and replaces the combination 5-FU + levamisol given over a period of one year in former times.
  • In the palliative situation 5-FU based therapy remains the goldstandard although more options than 5-FU plus folinic acid are now available.
  • Oxaliplatin and irinotecan are approved for the treatment of metastatic colon cancer in first line in combination with 5-FU.
  • Capecitabine and Ralitrexed are drugs, which are approved outside of Germany and can be used as well if indicated.
  • The median survival of patients with metastatic colon cancer is between 12 and 18 month.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Neoplasm Staging. Palliative Care. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11324309.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 61
  •  go-up   go-down


9. Scott RH, Mansour S, Pritchard-Jones K, Kumar D, MacSweeney F, Rahman N: Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol; 2007 Feb;4(2):130-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations.
  • Background A 13-year-old girl presented with rectal bleeding and was found to have two colonic carcinomas (stage Dukes' C) and multiple colonic polyps.
  • At the age of 7 years she had widespread hyperpigmented and hypopigmented skin lesions, and had developed medulloblastoma, which was treated with chemotherapy and craniospinal irradiation.
  • At the age of 10 years she had developed acute myelocytic leukemia, M5.
  • She was treated with chemotherapy including sibling bone marrow transplant with busulfan/cyclophosphamide conditioning.
  • A three-generation family history identified no relatives with colonic carcinomas or polyposis.
  • Investigations Immunohistochemical analysis was performed on a sample of colonic adenoma.
  • Management Cascade genetic testing and colonoscopic screening for colorectal carcinoma has been offered to relatives carrying one mutation.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Colonic Neoplasms / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Medulloblastoma / genetics


10. Gennatas C, Mouratidou D, Androulakis G, Georgoulias V, Tsavaris N, Philippakis M, Michailakis E, Kalofonos C, Mpesmpeas S, Katsos J, Tsitoura M, Retalis G, Mallas E, Voros D, Andreadis C, Hatzistylianos G, Pisiotis C, Kamilarios D, Kakoliris S, Komporozos V, Kannas D, Legakis N, Mpatakis T, Ntamtsios J, Papaevangelou E, Peros G, Photopoulos A, Pouli A, Prigouris S, Samanidis L, Sakellariou V, Smyrniotis V, Polymeneas G, Vasiliou J, Athanasiou A, Papadimitriou J: Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma. Tumori; 2002 Jan-Feb;88(1):32-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma.
  • AIMS AND BACKGROUND: Trials of adjuvant systemic therapy in high risk patients with Dukes' B2 and C colon cancer utilizing 5-fluorouracil-based regimens have been ongoing since the 1960s.
  • STUDY DESIGN: A total of 322 patients with histologically proven adenocarcinoma of the colon, Dukes' stage B2 and C, were entered in the study.
  • They were randomized to A) leucovorin 20 mg/m2 rapid intravenous injection and 5-FU 425 mg/m2 IV days 1-5 every 28 days for six cycles or B) 5-FU 600 mg/m2 24-hour infusion for five days, then 600 mg/m2 IV once a week and IFN 5 MU subcutaneously three times a week for six months.
  • These data do not support the use of IFN in combination with 5-FU as systemic adjuvant therapy for patients with locally advanced colon carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Interferon-alpha / administration & dosage. Leucovorin / administration & dosage. Male. Neoplasm Staging. Recombinant Proteins. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004847.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Fernández-Lobato B, Díaz-Carrasco MS, Pareja A, Marín M, Vila N, de la Rubia A: [Therapeutic use and profile of toxicity of the FOLFOX4 regimen]. Farm Hosp; 2009 Mar-Apr;33(2):89-95
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic use and profile of toxicity of the FOLFOX4 regimen].
  • [Transliterated title] Uso terapéutico y perfil de toxicidad del esquema FOLFOX4.
  • INTRODUCTION: Since the publication of the MOSAIC test results in 2004, the FOLFOX4 regimen has been established as an adjuvant treatment which is recommended in stage III colorectal cancer.
  • METHODS: Descriptive study of treatments with FOLFOX4 prescribed between April 2005 and March 2007.
  • The following data was collected: age, gender, diagnosis, stage of the illness (TNM classification) and adverse reactions, expressing severity according to Common Toxicity Criteria 2.0.
  • The diagnoses were: 28 colon cancer (4 stage II, 17 stage III, and 7 stage IV), 10 rectal cancer (1 stage II, 4 stage III, and 5 stage IV) and 1 stage IV gastric cancer.
  • ) When the study was completed, 9 patients continued active treatment with the regimen (average 6.8 cycles.
  • 14 patients stopped their treatment (an average of 8.1 cycles) due to toxicity in 10 cases, clinical progression in 3 cases and one patient died.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Leucovorin / adverse effects. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480796.001).
  • [ISSN] 1130-6343
  • [Journal-full-title] Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
  • [ISO-abbreviation] Farm Hosp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


12. George ML, Tutton MG, Abulafi AM, Eccles SA, Swift RI: Plasma basic fibroblast growth factor levels in colorectal cancer: a clinically useful assay? Clin Exp Metastasis; 2002;19(8):735-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma basic fibroblast growth factor levels in colorectal cancer: a clinically useful assay?
  • Angiogenic cytokines in the plasma and serum of cancer patients may serve as 'surrogate' markers of tumour neoangiogenesis.
  • Serum VEGF correlates with disease stage in colorectal cancer (CRC), but the role of bFGF in CRC is uncertain.
  • This study aimed to assess plasma bFGF levels in CRC patients before treatment, during chemoradiotherapy and at one-year follow-up.
  • There were no detectable differences between plasma bFGF levels in polyp, Dukes' A or B patients (4.55, 5.77, 4.25 pg/ml, respectively), but there was a significant increase in metastatic CRC patients [Dukes' C and D (7.42 and 6.6 pg/ml; P = 0.004 and 0.048, respectively)], relative to median control levels of 4.14 pg/ml.
  • At follow-up, there was a significant fall in plasma bFGF levels in disease-free patients (pre-op 6.09 and follow-up 3.45 pg/ml, P = 0.0004), but a non-significant rise in 18 patients with progressive disease (pre-treatment 5.90 and follow-up 9.99 pg/ml, P = 0.33).
  • Pre-treatment plasma bFGF in patients receiving chemo-radiotherapy was similar in those with responsive and non-responsive tumours.
  • There were no detectable changes in plasma bFGF through the adenoma-carcinoma sequence or patient groups with non-metastatic cancers.
  • Elevated plasma bFGF was, however, associated with metastatic spread.
  • The significant fall in bFGF in disease-free patients following therapy suggests that bFGF may be useful in clinical practice.
  • [MeSH-minor] Colonic Polyps / blood. Colonic Polyps / drug therapy. Colonic Polyps / radiotherapy. Colonic Polyps / surgery. Combined Modality Therapy. Humans. Reference Values

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12553380.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


13. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C, X-ACT Study Group: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol; 2003 Dec;14(12):1735-43
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
  • BACKGROUND: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer.
  • We report here the results of a large phase III trial investigating adjuvant oral capecitabine compared with 5-FU/LV (Mayo Clinic regimen) in Dukes' C colon cancer.
  • PATIENTS AND METHODS: Patients aged 18-75 years with resected Dukes' C colon carcinoma were randomized to receive 24 weeks of treatment with either oral capecitabine 1250 mg/m(2) twice daily, days 1-14 every 21 days (n = 993), or i.v. bolus 5-FU 425 mg/m(2) with i.v. leucovorin 20 mg/m(2) on days 1-5, repeated every 28 days (n = 974).
  • CONCLUSIONS: Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer.
  • Efficacy results are expected to be available in Keywords: Adjuvant treatment, capecitabine, chemotherapy, colorectal cancer

  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14630678.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement